Group 1 - The company is narrowing the technological gap in high-end products compared to international leaders in the medical dressing industry, such as 3M and Smith & Nephew [2] - Key raw material suppliers for the company are well-known within the industry, indicating a strong supply chain [2] - The company utilizes advanced production equipment and has established a mature and stable production line, meeting quality control requirements of both domestic and international clients [2] - The company plans to continue enhancing its research and development efforts to further improve its technological capabilities and reduce the gap with international competitors [2]

格隆汇8月12日丨健尔康(603205.SH)在互动平台表示，公司目前在肯尼亚没有相关产品的业务。如有相 关信息依据规则要求达到披露标准，公司将根据相关规则要求及时履行信息披露义务。 ...

Core Viewpoint - The IPO process of Aisheren Medical Technology Group Co., Ltd. has faced setbacks due to the suspension of its listing application by the Beijing Stock Exchange, attributed to the expiration of financial documentation [1] Group 1: Company Overview - Aisheren focuses on rehabilitation care products and surgical infection control products, with a product line that includes medical care pads, medical ice bags, surgical gowns, and surgical drapes [1] - The company plans to raise 300 million yuan through its IPO for the construction of a public health medical supplies industrial park under its wholly-owned subsidiary, Anhui Kaipule Medical Technology Co., Ltd. [1] Group 2: Financial Performance - Aisheren has shown stable revenue growth from 2021 to 2024, with revenues of 573 million yuan, 574 million yuan, 575 million yuan, and 692 million yuan respectively, achieving a revenue growth rate of 20.36% in 2024 [1] - In contrast, comparable companies in the industry, such as Aomei Medical, Zhend Medical, and Jianer Kang, experienced revenue declines in 2023, while Aisheren's revenue increased [1] Group 3: Market Dynamics - The company's growth is significantly supported by its expansion into overseas markets, with a notable increase in sales revenue from the United States [1] - In 2023, Aisheren achieved positive growth in sales revenue from foreign customers, while domestic sales revenue declined, mirroring the performance of some industry peers [1] Group 4: Profitability Challenges - Despite stable revenue growth, Aisheren's profitability is relatively low compared to its peers, with gross margins consistently below the industry average [4] - The decline in gross margin for surgical infection control products is attributed to a decrease in prices following a resolution of resource shortages, while the gross margin for rehabilitation care products fell due to rising raw material costs and price reductions to secure more orders [4] Group 5: Customer Concentration - Aisheren has a high customer concentration, with over 78% of revenue coming from its top five customers, which has been increasing year by year [5] - This high customer concentration may impact the company's profitability, similar to the situation faced by Jianer Kang, which has a comparable gross margin and customer concentration [5] Group 6: Future Outlook - Although the IPO process is currently on hold, Aisheren's stable performance and deep collaborations with global medical device leaders provide a solid foundation for future development [9] - Key challenges for Aisheren moving forward include improving profitability and reducing customer concentration risk [9]

证券代码：603205 证券简称：健尔康 公告编号：2025-018 健尔康医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： A 股每股现金红利0.351元 每股转增股份0.3股 三、 相关日期 相关日期 | 股份类别 | 股权登记日 | 新增无限售 最后交易日 除权（息）日 条件流通股 | | --- | --- | --- | | | | 份上市日 | | Ａ股 | 2025/7/8 | － 2025/7/9 2025/7/9 2025/7/9 | | | | 现金红利发 放日 | 差异化分红送转： 否 一、 通过分配、转增股本方案的股东大会届次和日期 本次利润分配及转增股本方案经公司2025 年 5 月 13 日的2024年年度股东大会审议通过。 公司不存在首发战略配售股份 每股分配比例，每股转增比例 二、 分配、转增股本方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本 ...

Core Viewpoint - The announcement details the change of the sponsor representative for Jianer Kang Medical Technology Co., Ltd. due to the work relocation of the previous representative, ensuring the continuity of supervision during the IPO process [1]. Group 1: Change of Sponsor Representative - Jianer Kang Medical Technology Co., Ltd. received a notice from CITIC Securities regarding the change of its sponsor representative for the ongoing IPO supervision [1]. - The original representatives were Zhu Beihang and Lü Yan, with the supervision period lasting until December 31, 2026 [1]. - Zhu Beihang will be replaced by Hao Yongchao to maintain orderly supervision [1]. Group 2: Acknowledgment and New Representative's Background - The company expresses gratitude for Zhu Beihang's contributions during the supervision period [1]. - Hao Yongchao holds a master's degree and is a qualified Chinese CPA, currently serving as a senior vice president at CITIC Securities [3]. - Hao Yongchao has participated in various IPO projects, demonstrating a strong background in the field [3].

本次保荐代表人变更后，公司首次公开发行股票并在主板上市持续督导保荐 代表人为吕岩先生和郝勇超先生。 公司对朱北航先生在持续督导期间所作出的贡献表示衷心感谢！ 特此公告。 附件：保荐代表人简历 健尔康医疗科技股份有限公司 董事会 证券代码：603205 证券简称：健尔康 公告编号：2025-017 健尔康医疗科技股份有限公司 关于变更保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健尔康医疗科技股份有限公司（以下简称"公司"）近日收到保荐机构中信 建投证券股份有限公司（以下简称"中信建投证券"）出具的《关于变更健尔康 医疗科技股份有限公司首次公开发行股票并在主板上市持续督导保荐代表人的 函》。中信建投证券作为公司首次公开发行股票并在主板上市的保荐人，原指派 朱北航先生和吕岩先生担任保荐代表人负责保荐工作及持续督导工作，持续督导 期至2026年12月31日止。现因朱北航先生工作变动，不再担任公司持续督导的保 荐代表人，为保证持续督导工作的有序进行，中信建投证券委派郝勇超先生接替 朱北航先生担任公司保荐代表人，继续 ...

Group 1 - The company, Jianerkang Medical Technology Co., Ltd., will hold its 2024 annual performance briefing on June 5, 2025, from 10:00 to 11:00 AM [2][3] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [3][4] - Key personnel attending the meeting include the Chairman, General Manager, Secretary of the Board, Chief Financial Officer, Independent Director, and Sponsor Representative [3] Group 2 - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center website and will have the opportunity to ask questions [4] - Questions can be submitted from May 28, 2025, to June 4, 2025, before 4:00 PM through the website or via the company's email [4] - After the briefing, investors can view the meeting's details and main content on the Shanghai Stock Exchange Roadshow Center [4]

证券代码：603205 证券简称：健尔康 公告编号：2025-016 健尔康医疗科技股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二） 会议召开地点：上证路演中心 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 05 月 28 日（星期三）至 06 月 04 日（星期 三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 lp@chinajek.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 健尔康医疗科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 23 日发布公司 2024 年年度报告，为便于广大投资者更全面深入 地了解公司 2024 年度经营成果、财务状况，公司计划于 2025 年 06 月 05 日（星期四）10:00-11:00 举行 2024 年度业绩说明会，就投资 者关心的问题进行交流。 一、 说 ...

Group 1 - The annual general meeting of shareholders for Jianerkang Medical Technology Co., Ltd. was held on May 13, 2025, at the company's office in Changzhou, Jiangsu Province [2] - All resolutions presented at the meeting were approved without any objections [2] - The meeting was attended by all nine current directors, three supervisors, and the company secretary, ensuring full representation [2][3] Group 2 - The following proposals were approved during the meeting: 1. 2024 Annual Board Work Report 2. 2024 Annual Supervisory Board Work Report 3. 2024 Financial Settlement Report 4. 2025 Financial Budget Report 5. 2024 Annual Report and its Summary 6. 2024 Profit Distribution and Capital Reserve Fund Conversion Plan 7. Reappointment of the accounting firm 8. 2025 Director Remuneration Plan 9. 2025 Supervisor Remuneration Plan 10. Application for comprehensive credit line from banks [3][4][5] - Separate voting was conducted for proposals 6, 7, and 8 to ensure the interests of minority investors were considered [5] Group 3 - The meeting was witnessed by Shanghai Guangfa Law Firm, confirming that the procedures followed were in compliance with relevant laws and regulations [5] - The legal representatives concluded that the meeting's convening and voting processes were valid and lawful [5]

2024年年度股东大会的法律意见书 上海市广发律师事务所 关于健尔康医疗科技股份有限公司 本次股东大会现场会议于 2025年 5 月 13 日 14 时 00 分在公司会议室召开; 网络投票采用上海证券交易所网络投票系统,通过交易系统投票平台进行投票的 时间为股东大会召开当日的交易时间段,即 9:15-9:25,9:30-11:30,13:00-15:00, 通过互联网投票平台投票的具体时间为股东大会召开当日的 9:15-15:00。 公司已向本所保证和承诺,公司向本所律师所提供的文件和所作的陈述和说 明是完整的、真实的和有效的,有关原件及其上面的签字和印章是真实的,且一 切足以影响本法律意见书的事实和文件均已向本所披露,而无任何隐瞒、疏漏之 处。 在本法律意见书中,本所律师根据《股东会规则》的要求,仅就本次股东大 会的召集、召开程序是否合法及是否符合《公司章程》、出席会议人员资格和会 议召集人资格的合法有效性、会议表决程序和表决结果的合法有效性发表意见, 而不对本次股东大会所审议的议案内容和该等议案中所表述的事实或数据的真 实性和准确性发表意见。 l 本法律意见书仅供本次股东大会之目的使用,不得被任何人用于 ...